
Brian Schulte, MD, discusses the ongoing phase 2 PRECISION 1 basket trial evaluating the use of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring TSC1/2 mutations.

Your AI-Trained Oncology Knowledge Connection!


Brian Schulte, MD, discusses the ongoing phase 2 PRECISION 1 basket trial evaluating the use of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring TSC1/2 mutations.

Brian Schulte, MD, discusses the prevalence of TSC1/TSC2 mutations in cancer.

Published: November 14th 2022 | Updated: